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The p53-related p63 gene encodes six isoforms with differing N and C termini. TAp63 isoforms possess a
transactivation domain at the N terminus and are able to transactivate a set of genes, including some targets
downstream of p53. Accumulating evidence indicates that TAp63 plays an important role in regulation of cell
proliferation, differentiation, and apoptosis, whereas transactivation-inert Np63 functions to inhibit p63 and
other p53 family members. Mutations in the p63 gene that abolish p63 DNA-binding and transactivation
activities cause human diseases, including ectrodactyly ectodermal dysplasia and facial clefting (EEC) syn-
drome. In this study, we show that mutant p63 proteins with a single amino acid substitution found in EEC
syndrome are DNA binding deficient, transactivation inert, and highly stable. We demonstrate that TAp63
protein expression is tightly controlled by its specific DNA-binding and transactivation activities and that p63
is degraded in a proteasome-dependent, MDM2-independent pathway. In addition, the N-terminal transacti-
vation domain of p63 is indispensable for its protein degradation. Furthermore, the wild-type TAp63 can act
in trans to promote degradation of mutant TAp63 defective in DNA binding, and the TA domain deletion
mutant of TAp63 inhibits transactivation activity and stabilizes the wild-type TAp63 protein. Taken together,
these data suggest a feedback loop for p63 regulation, analogous to the p53-MDM2 feedback loop.
The p63 gene is a recently discovered member of the p53
gene family (38). Unlike p53, p63 has six different isoforms.
The transactivation (TA) isoforms, which resemble p53, are
generated by the use of an upstream promoter and consist of
an acidic N-terminal transactivation domain, a central DNA-
binding domain, and a C-terminal oligomerization domain (25,
39). The primary amino acid sequences in the DNA-binding
domains of p63 and p53 share over 60% identity, whereas in
the TA domain they share 25% identity. TAp63 isoforms are
capable of transactivating a set of target genes, some of which
overlap with targets downstream of p53, including Bax,
MDM2, and p21 (39). The N isoforms, produced from an
intronic promoter, contain the same DNA-binding and oli-
gomerization domains as the TA isoforms but lack the trans-
activation domain. The N isoforms also contain a region of 26
amino acids (aa) at the very N-terminal end of the protein
(TA2) in which an activation function was recently identified
(7). In addition, the N isoforms are capable of forming pro-
tein complexes with p53 family proteins to inhibit the function
of p53 family members (39). Furthermore, both the TAp63 and
Np63 isoforms can undergo alternative splicing to yield three
different C-terminal tails (TAp63, -, and - isoforms and
Np63, -, and - isoforms). Among these isoforms, TAp63
is the most transactivation-active isoform of p63 (39). In the
C-terminal extension of the -isoforms, there is a sterile alpha
motif implicated in protein-protein interactions and thought to
be important for mammalian development (32).
Despite their structural homology, the p53 family members
have distinctive biological functions. While p53 is a key gate-
keeper for genomic stability by regulating cell cycle, DNA
damage repair, and apoptosis, p73 and p63 are critical during
development and differentiation. In particular, p63 appears to
be essential in epithelial and limb development as demon-
strated by the mouse models (33). Several dominant human
syndromes involving limb development and ectodermal dyspla-
sia have been mapped to the p63 gene, including ectrodactyly,
ectodermal dysplasia and cleft lip/palate (EEC) syndrome;
nonsyndromic split hand/foot malformation (SHFM); anky-
loblepharon, ectodermal dysplasia, clefting (AEC) syndrome;
acro-dermato-ungual-lacrimal-tooth (ADULT) syndrome; and
limb-mammary syndrome (LMS) (2, 4). Most mutations in the
p63 gene identified in EEC patients so far result in amino acid
substitutions that are predicted to abolish the DNA-binding
capacity of p63. In contrast to p53, the p63 gene is rarely
mutated in cancer (12, 21, 25). However, overproduction of
Np63 isoforms has been reported in squamous cell carcinoma
(10) and in many other types of epithelial tumors (6, 24, 26,
27).
The p53 protein is usually labile in normal cells but is dra-
matically stabilized upon a variety of cellular stresses. The key
negative regulator of p53 is the MDM2 protein, which func-
tions as an E3 ubiquitin ligase for p53 to promote its protein
degradation (9, 15). In addition, MDM2 physically binds to the
p53 N-terminal transactivation domain, thereby directly inhib-
iting p53 transactivation activity (5). Importantly, MDM2 is a
bona fide target gene downstream of p53. Thus, activation of
* Corresponding author. Mailing address: Department of Biochem-
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p53 up-regulates its own inhibitor (MDM2). This feedback
loop ensures that p53 protein levels are maintained at low
levels in normal cells.
Here we show that, like p53, the protein stability of the
transactivation form of p63, TAp63, is also tightly regulated
by its DNA-binding and transactivation activities. The N-ter-
minal TA domain is required for its protein degradation inde-
pendent of MDM2. Our data suggest that TAp63 is regulated
through a feedback mechanism similar to the p53-MDM2
feedback loop.
MATERIALS AND METHODS
Cell culture and drug treatment. U2-OS, HeLa, and Saos-2 cells were main-
tained in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with
10% fetal bovine serum (FBS) and 1% penicillin G/streptomycin sulfate at 37°C
in a humidified 5% CO2 incubator. Wild-type or p53/ MDM2/ mouse
embryonic fibroblasts (MEF) were maintained in DMEM supplemented with
15% FBS. U2-OS-Tet-TAp63 and U2-OS-Tet-Luciferase cells were maintained
in DMEM supplemented with 10% FBS, 2 g/ml doxycycline (BD Biosciences–
Pharmingen), and 200 g/ml hygromycin (BD Biosciences–Pharmingen).
Plasmid construction and transfection. pcDNA-myc-TAp63 and pcDNA-
myc-Np63 were described previously (39). A BamHI/XhoI or BamHI/XbaI
PCR fragment containing TAp63 was subcloned into pcDNA-HA or pTRE-
tight (BD Biosciences–Pharmingen) to generate pcDNA-HA-TAp63 or pTRE-
tight-TAp63. The pcDNA-myc-TAp63 and pcDNA-HA-TAp63 plasmids
were used to generate deletion mutants or point mutants by site-directed mu-
tagenesis according to the manufacturer’s instructions (Stratagene). The TA
domain swapping mutant of TAp63, HA-p53TA-p63, was generated from
pcDNA-HA-TAp63 and pcDNA-HA-p53 (40) using overlapping extension as
described previously (11). All constructs were confirmed by DNA sequencing.
U2-OS and HeLa cells were transfected with FuGENE 6 (Roche). Saos-2 cells
were transfected with CalPhos transfection kit (BD Biosciences–Pharmingen).
MEF were transfected with Lipofectamine 2000 (Invitrogen). To examine
FIG. 1. The transactivation activity of p63 correlates with its protein stability. (A) TAp63 and Np63 were transiently expressed in U2-OS
and HeLa cells. Cell lysates were subjected to Western blot analysis for p63 and actin. V, vector. (B) U2-OS or HeLa cells transfected with TAp63
and Np63 expression plasmids were treated with proteasome inhibitor MG132 (). Cell lysates were subjected to Western blot analysis. The
endogenous p53 protein levels were also analyzed. (C) U2-OS cells transiently transfected with TAp63 or Np63 were treated with cyclohex-
imide (CHX) for the indicated times (in hours). Equal amounts of total proteins were subjected to Western blot analysis for p63. Quantitation of
the p63 protein bands was performed using densitometry scanning and presented as a percentage of the remaining p63 protein level.
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TAp63 protein stability, U2-OS or HeLa cells were transfected with 500 ng of
pcDNA-TAp63 or cotransfected with 500 ng of pcDNA-TAp63 and 1.0 g of
either pcDNA-TAp63(R304W), pcDNA-TAp63, or pcDNA-TAp63(FWL-
A). Sixteen hours posttransfection, cells were treated with cycloheximide (Sigma)
at a final concentration of 50 g/ml. Cells were collected at time intervals. For
MG132 treatment, cells transfected for 30 h were treated with MG132 (20 M)
(Sigma) for 5 h. To generate U2-OS-Tet-TAp63 and U2-OS-Tet-Luc cells,
U2-OS-Tetoff cells (gift from Qiang Yu, Boston University School of Medicine)
were cotransfected with 5 g of pTRE-tight-TAp63 or pTRE-tight-Luciferase
(BD Biosciences–Pharmingen) and 0.5 g of pTK-Hyg. Twelve hours posttrans-
fection, cells were selected with doxycycline (2 g/ml) and hygromycin (400
g/ml) for 4 weeks. Single colonies were selected. All clonal cell lines were tested
for induction of TAp63 or luciferase in the absence of doxycycline by Western
blot analysis or luciferase activity assay. A stable U2-OS-TetTAp63 cell line
(clone 2) was chosen for further analysis for its effective repression and induction
by doxycycline administration or withdrawal.
Luciferase reporter assay and Western blot analysis. For luciferase report
assay, Saos-2 cells grown in six-well tissue culture dishes at 80% confluence were
transfected with 100 ng of either wild-type or mutant pcDNA-TAp63 in the
presence of 2 g of Bax-Luciferase (Bax-Luc) and 100 ng of pCMV--galacto-
sidase plasmids. To examine the dominant-negative effect of p63 mutants, Saos-2
cells were transfected with 100 ng of pcDNA-myc-TAp63, 400 ng of either
pcDNA-HA-TAp63 or pcDNA-HA-TAp63(R304W) in the presence of 2 g
of Bax-Luc and 100 ng of pCMV--galactosidase. Thirty-six hours posttransfec-
tion, cells were harvested in 1 reporter lysis buffer (BD Biosciences–Pharmin-
gen) and subjected to -galactosidase assay and luciferase activity assay (BD
FIG. 2. The DNA-binding activity of p63 is essential for its protein
degradation. (A) Saos-2 cells were transfected with either wild-type
(WT) TAp63 or a mutant TAp63 defective in DNA binding
(R204W, R304W, or C306R) in the presence of Bax-Luciferase re-
porter and -galactosidase plasmids. Cell lysates were subjected to
luciferase and -galactosidase assays. The luciferase activity was nor-
malized to -galactosidase activity and reported as an increase in
activation (mean 	 standard deviation [error bar]). (B) U2-OS cells
transfected with an indicated plasmid were treated with MG132 ().
Cell lysates were subjected to Western blot analysis. (C) U2-OS cells
transfected with TAp63 or TAp63(R304W) were treated with cy-
cloheximide (CHX) for the indicated times (in hours). Cell lysates
were subjected to Western blot analysis for p63 and actin.
FIG. 3. The transactivation activity of p63 is critical for its protein
degradation. (A) Saos-2 cells transfected with wild-type (WT) TAp63
or a mutant TAp63, either lacking the TA domain (TAp63) or
defective in DNA binding (R204W and R304W) in the presence of
Bax-Luciferase reporter and -galactosidase plasmids. The luciferase
activity was normalized to -galactosidase activity and reported as an
increase in activation (mean 	 standard deviation [error bar]).
(B) Protein expression was examined by Western blot analysis. V,
vector. (C) U2-OS cells transfected with TAp63 or TAp63 were
treated with cycloheximide (CHX) for the indicated times (in hours).
Cell lysates were subjected to Western blot analysis.
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Biosciences–Pharmingen). Luciferase activity was normalized to -galactosidase
activity and presented as the mean 	 standard deviation of three independent
experiments performed in triplicate.
For Western blot analysis, cells were lysed in EBC buffer (50 mM Tris-HCl,
pH 8.0, 250 mM NaCl, 0.5% Nonidet P-40, 0.2 mM phenylmethylsulfonyl fluo-
ride [PMSF], 2 g/ml leupeptin, 2 g/ml aprotinin, 50 mM NaF, and 0.5 mM
Na3VO4). Equal amounts of total protein were subjected to sodium dodecyl
sulfate-polyacrylamide gel electrophoresis and Western blot analysis. Antibodies
used were specific for p63 (4A4; Santa Cruz), hemagglutinin (HA) (Y-11; Santa
Cruz), p53 (DO-1; Santa Cruz), Myc (9E10; Santa Cruz), -galactosidase (23781;
Promega), and actin (C-11; Santa Cruz).
Electrophoresis mobility shift assay (EMSA). H1299 cells were transfected
with 3 g of p53 or a TAp63 construct. Twenty-four hours posttransfection,
nuclear extracts were prepared. Briefly, cells were collected and lysed in hypo-
tonic buffer (10 mM HEPES, pH 7.6, 1.5 mM MgCl2, 10 mM KCl, 0.5 mM
dithiothreitol [DTT], 0.5 mM PMSF, 0.2% Nonidet P-40), followed by centrif-
ugation at 4,000 rpm for 10 min at 4°C. The pellets were then lysed in hypertonic
buffer (20 mM HEPES, pH 7.6, 1.5 mM MgCl2, 420 mM NaCl, 0.5 mM DTT, 0.5
mM PMSF, 25% glycerol), followed by centrifugation at 14,000 rpm for 20 min
at 4°C. The reaction mixture (total volume of 25 l) containing 20 g nuclear
extracts in binding buffer [10 mM HEPES, pH 7.5, 50 mM NaCl, 1 mM DTT, 1
mM EDTA, 5% glycerol, 0.25 g/l bovine serum albumin, and 0.1 g/l of
poly(dI-dC)] was incubated at room temperature for 20 min. The competition
assay was performed by the addition of 50-fold excess of unlabeled wild-type
oligonucleotide (sc-2579; Santa Cruz Biotechnology) or mutant oligonucleotide
(sc-2580; Santa Cruz Biotechnology) into the reaction mixture and incubation for
20 min prior to the addition of 32P-labeled probe. DNA-protein complexes were
resolved by electrophoresis on 4% polyacrylamide gels in Tris-glycine buffer and
revealed by autoradiography. Thirty nanograms of oligonucleotide containing
the p53-binding consensus site (sc-2579; Santa Cruz Biotechnology) was end
labeled in the presence of 25 Ci of [32P]ATP (NEG002H; New England
Nuclear) and 10 U of T4 polynucleotide kinase (M0201; New England BioLabs)
for 30 min at 37°C.
Immunofluorescence staining. U2-OS cells in six-well plates were cotrans-
fected with either 500 ng of pcDNA vector or pcDNA-TAp63, or 200 ng of
pcDNA-TAp63(R304W), pcDNA-TAp63(C306R), pcDNA-TAp63(FWL-A), or
pcDNA-TAp63(TA) in the presence of 50 ng of pEG-GFP using FuGENE 6.
Twelve hours posttransfection, cells were trypsinized and 5  104 cells were
plated onto Lab-Tek II chamber slides (154461; Nalge Nunc International).
Twenty-four hours later, cells were fixed in 4% paraformaldehyde (in phosphate-
buffered saline, pH 7.4), permeabilized with 0.2% Triton X-100, blocked in
phosphate-buffered saline containing 1% bovine serum albumin, and then im-
munostained with p63 antibody (sc-8431; Santa Cruz Biotechnology) followed by
a Cy3-conjugated goat anti-mouse immunoglobulin G antibody (115-165-146;
Jackson ImmunoResearch Laboratory). The cells were counterstained with 4
,6
-
diamidino-2-phenylindole (DAPI) (300 nM) prior to mounting using ProLong
Gold Antifade (P36930; Molecular Probes). Staining was visualized using the
following excitation/emission wavelengths: 358/461 nm for DAPI, 595/615 nm for
Cy3, and 494/518 nm for green fluorescent protein (GFP). Fluorescent images
were captured on a Zeiss Axiovert 200M microscope with Axiovision v 4.3
program.
RESULTS
p63 protein instability correlates with its transactivation
activity. It is well documented that the predominant species of
p63 in epithelial cells and cancer cells are N isoforms, which
lack the transactivation domain at the N terminus, whereas the
levels of TA isoforms are very low under physiological condi-
tions (10, 20, 38). We asked whether this phenomenon is rem-
iniscent of p53, whose mutants defective in transactivation
activity unavoidably become stabilized. Thus, we examined the
protein expression levels of transactivation-potent TAp63
and transactivation-inert Np63 in U2-OS or HeLa cells by
transient transfection. As shown in Fig. 1A, the protein levels
of TAp63 were significantly less than those of Np63 in both
cell lines. Treatment with proteasome inhibitor MG132 led to
stabilization of endogenous p53 proteins, as expected, and to a
dramatic increase of TAp63 protein levels. Np63 protein
was also stabilized, albeit to a much lesser extent (Fig. 1B).
These data suggest that TAp63 is degraded through a pro-
teasome-dependent pathway and that the differences in the
protein levels of ectopically expressed TAp63 and Np63
are likely due to different protein turnover rates. Thus, we
performed cycloheximide treatment to determine the protein
half-lives of TAp63 and Np63 in U2-OS cells. As shown in
Fig. 1C, TAp63 exhibited a much shorter half-life (90 min)
than Np63 did (5 hours). These data revealed a correla-
tion between the transactivation activity and protein stability of
p63 isoforms.
The specific DNA-binding and transactivation activities of
TAp63 are essential for its protein degradation. Mutations in
the p63 gene have been linked to several human genetic dis-
eases, including EEC syndrome and SHFM (33). In EEC syn-
drome and SHFM, the germ line mutations in the p63 gene are
FIG. 4. The mutant TAp63(FWL-A) bearing three point muta-
tions at the FWL motif in the TA domain retains partial transactiva-
tion activity but is highly stable. (A) The FWL motif (indicated by
asterisks) is evolutionarily conserved among p53 family members.
Gaps introduced to maximize alignment are indicated by dashes. Hu,
human; Mu, murine. (B) Saos-2 cells were transfected with wild-type
or mutant TAp63(FWL-A) in the presence of Bax-Luciferase and
-galactosidase constructs. The luciferase activity was normalized to
-galactosidase activity and reported as an increase in activation
(mean 	 standard deviation [error bar]). V, vector. (C) U2-OS cells
transfected with TAp63 or TAp63(FWL-A) were treated with cy-
cloheximide (CHX) for the indicated times (in hours). Cell lysates
were subjected to Western blot analysis for p63 and actin.
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frequently located in the central DNA-binding domain (4, 34,
36). Strikingly, these missense mutations correspond very well
with the somatic mutational hot spots in the p53 gene, which
inactivate p53 DNA binding and p53 growth suppression func-
tion. We generated three point mutations in the DNA-binding
domains of TAp63, TAp63(R204W), TAp63(R304W), and
TAp63(C306R). These mutations are found in EEC syn-
drome and are predicted to abolish the DNA-binding activity
FIG. 6. The TA domain of p63 is essential for its protein instability independent of MDM2. (A) Saos-2 cells were transfected with wild-type TAp63
or a chimeric construct (HA-p53TAp63) in the presence of Bax-Luciferase and -galactosidase constructs. The luciferase activity was normalized to
-galactosidase activity and reported as an increase in activation (mean 	 standard deviation [error bar]). (B) Saos-2 (p53) or U2-OS (p53) cells
transfected with wild-type HA-TAp63 or HA-p53TA-p63 were treated by cycloheximide (CHX) for the indicated times (in hours). Cell lysates were
subjected to Western blot analysis using antibodies specific for HA tag or actin. (C) Cell lysates (50 g of total protein) from U2-OS or Saos-2 cells were
subjected to Western blot analysis for MDM2 or actin. (D) Wild-type (WT) or p53/ MDM2/ MEF were transfected with TAp63, followed by
cycloheximide (CHX) treatment for the indicated times (in hours). Cell lysates were subjected to Western blot analysis using antibody specific for p63.
FIG. 5. The mutant TAp63 proteins defective in DNA binding or in transactivation are nuclear and stable. (A) H1299 cells were transfected with
an indicated p53 or TAp63 expression plasmid. Equal amounts of nuclear extracts were subjected to EMSA using a 32P-labeled p53 oligonucleotide
(Oligo) (top panel). Cold competition was performed using either the wild-type (wt) p53 oligonucleotide (lanes 3 and 6) or a mutant (mt) p53
oligonucleotide (lanes 4 and 7). Expression of ectopically expressed p53 or p63 proteins was shown by Western blot analysis for p53, p63, and actin
(bottom panel). V, vector. (B) Dose effects of wild-type or mutant TAp63 on transactivation activity. Saos-2 cells were transfected with the indicated
amounts of wild-type or mutant TAp63 [TAp63(FWL-A) or TAp63(R304W)] in the presence of Bax-Luciferase reporter and pCMV--galactosidase
plasmids. Equal amounts of total proteins (20 g) were subjected to Western blot analysis for p63 and actin (top panel) or to assays measuring luciferase
and -galactosidase activities. The luciferase activity was normalized to -galactosidase activity and reported as an increase in activation (n-fold) (mean
	 standard deviation [error bar]) (bottom panel). V, vector. (C) U2-OS cells were cotransfected with wild-type or mutant TAp63 and GFP expression
plasmids. Thirty-six hours posttransfection, cells were fixed and subjected to immunohistochemical staining with p63-specific antibody (4A4). Nuclei were
costained with DAPI. Coexpressed GFP is shown (magnification of 400).
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of p63 (4). Indeed, all three mutant proteins exhibited no
DNA-binding activity (see Fig. 5A) and, as expected, no de-
tectable transcriptional activity (Fig. 2A), yet they were ex-
pressed at much higher levels than wild-type TAp63 (Fig. 2B).
Inhibition of proteasomes led to a dramatic increase in protein
stability of wild-type TAp63 but not the p63 mutant proteins
defective in DNA binding (Fig. 2B). Indeed, the mutant pro-
teins exhibited significantly prolonged protein half-lives (Fig.
2C and data not shown). Thus, these data indicate that the
specific DNA-binding activity of TAp63 is essential for its
protein degradation.
To further demonstrate the link between the transactivation
activity of TAp63 and its protein degradation, we generated
an N-terminal deletion mutant of TAp63, TAp63, which
lacks the entire TA domain (aa 1 to 69). Although TAp63
possessed a strong DNA-binding activity (see Fig. 5A) and
localized in nuclei (see Fig. 5C), it exhibited no transactivation
activity (Fig. 3A) and was highly stable (Fig. 3B and C). There-
fore, these data indicate that the transcriptional activity of
TAp63 is critical for its protein instability.
The FWLmotif in the TA domain is essential for p63 protein
degradation. The p53-MDM2 feedback regulation is a well-
established mechanism for the control of p53 protein levels.
Three hydrophobic amino acids within the p53 N terminus,
F19 W23 L26, which are buried in a cleft within the interface
between p53 and MDM2, are critical for the MDM2-mediated
degradation of p53 protein (16). Despite a poor homology
(25%) among the p53 family members in the N-terminal trans-
activation domain, the FWL motif is well conserved (Fig. 4A).
Therefore, we examined whether the FWL motif is also critical
for p63 degradation. As shown in Fig. 4, the triple point mu-
tant, TAp63(FWL-A) in which these three amino acid resi-
dues (F16, W20, and L23) are replaced by alanine, retained
strong DNA-binding activity (Fig. 5A) and partial transactiva-
tion activity in a dose-dependent manner (Fig. 4B and 5B), yet
the protein was highly stable (Fig. 4C). These data suggest
either that the partial transactivation activity is insufficient to
promote p63 protein degradation or that the FWL motif is
critical for p63 protein turnover. To address this question, we
generated a HA-tagged chimeric protein HA-p53TA-p63 in
which the TA domain (aa 1 to 64) of TAp63 is replaced with
the TA domain (aa 1 to 45) of p53. As shown in Fig. 6,
p53TA-p63 was fully competent in transactivation (Fig. 6A).
Strikingly, it was stable in Saos-2 cells (Fig. 6B), indicating that
the transactivation activity alone is not sufficient for protein
degradation. However, in contrast to remarkable protein sta-
bility in Saos-2 cells, p53TA-p63 protein was rapidly turned
over in U2-OS cells (Fig. 6B). Since U2-OS cells contain wild-
type p53 and express much higher levels of MDM2 in compar-
ison to the p53 null Saos-2 cells (Fig. 6C), it is likely that
degradation of the p53TA-p63 chimeric protein is dependent
on MDM2, which binds to the TA domain of p53. Of note, the
FWL motif is important for p53 interaction with MDM2 (16).
Thus, the conserved FWL motif in the TA domain of TAp63
may serve as a binding site for MDM2, which might in turn
promote p63 degradation. However, the ectopically expressed
TAp63 exhibited similar protein half-lives in wild-type MEF
and p53/ MDM2/ MEF (Fig. 6D), indicating that degra-
dation of TAp63 does not require MDM2. Thus, the FWL
motif in the TA domain of TAp63 is critical for its protein
degradation in an MDM2-independent manner.
Wild-type TAp63 can act in trans to promote degradation
of the p63 DNA-binding mutant, but not the p63 TA domain
mutants. Since both the transcriptional activity and the FWL
motif of TAp63 are crucial for its protein instability, it is very
possible that there may be a feedback control mechanism for
regulation of p63 protein levels, analogous to the p53-MDM2
feedback loop. This hypothesis would predict that TAp63
transactivates expression of an unidentified target gene whose
product interacts with the FWL motif in the TA domain to
promote TAp63 protein degradation via a proteasome-de-
pendent pathway. Accordingly, the wild-type TAp63 should
be able to act in trans to promote the degradation of mutant
FIG. 7. TAp63 can act in trans to promote degradation of the p63
DNA-binding mutant, but not the p63 TA domain mutants. U2-OS
cells were cotransfected with Myc-tagged wild-type TAp63 and a
HA-tagged TAp63 mutant, HA-TAp63(R304W) (A), HA-
TAp63(FWL-A) (B), or HA-TAp63 (C). Cells were then treated
with cycloheximide (CHX) for the indicated times (in hours). Cell
lysates were subjected to Western blot (WB) analysis using antibodies
specific for HA tag or actin. Quantitative analysis of the data in panel
A was performed.
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p63 protein defective in DNA binding, but not the mutant p63
lacking the TA domain or the mutant p63 with a defective
FWL motif. Indeed, in cotransfection experiments, the protein
half-life of HA-tagged TAp63(R304W) was decreased by
50% in the presence of Myc-tagged wild-type TAp63, while
the half-life of HA-tagged TAp63 or TAp63(FWL-A) was
not affected by the presence of wild-type TAp63 (Fig. 7). A
similar phenomenon was observed using an inducible U2-OS-
Tet-TAp63 stable cell line. Upon withdrawal of doxycycline,
expression of TAp63 was markedly induced (Fig. 8C). Induc-
tion of TAp63, but not induction of luciferase in the control
cell line, led to a significant decrease in the protein half-life
(2 h) of HA-TAp63(R304W) (Fig. 8A and B).
It has been shown that nontransactivation Np63 isoforms
are predominantly expressed in cancer cells and in epithelial
progenitor cells (10, 20, 38). We therefore investigated the
influence of transactivation-inert p63 mutant TAp63 on the
wild-type TAp63 protein stability. As shown in Fig. 9, coex-
pression of TAp63 led to a marked suppression of transac-
tivation activity and significant stabilization of TAp63 protein.
Interestingly, coexpression of DNA-binding-defective TAp63
(R304W) exhibited a much lower inhibitory effect on the
TAp63 transactivation activity and no significant effect on the
stability of TAp63 protein (Fig. 9). Thus, nontransactivation
TAp63 can effectively function in a dominant-negative fash-
ion in suppression of transactivation activity of wild-type
TAp63 and modulate the stability of transactivation p63 iso-
forms.
DISCUSSION
Although the regulation of p53 protein stability has been
extensively studied, how p63 protein stability is regulated is
largely unknown (19). Here we demonstrate that the transac-
tivation-potent species of p63, TAp63, is tightly regulated
likely through a feedback mechanism, analogous to the p53-
Mdm2 feedback loop (Fig. 10). We show that both DNA-
binding and transactivation activities are essential for TAp63
instability and, furthermore, that the unique features of the
TAp63 TA domain play an important role in protein degra-
dation. Moreover, we show that the wild-type TAp63 can act
in trans to induce the degradation of the p63 DNA-binding
mutant and that the p63 deletion mutant lacking the TA do-
main can stabilize the TAp63 protein through its dominant-
negative effect.
p53 is frequently mutated in human cancers with a high
frequency of point mutations, referred to as hot spots, in the
DNA-binding domain. These mutant p53 proteins are usually
stable, since they are incapable of inducing the expression of
MDM2 (22). Strikingly, many of the naturally occurring p63
mutations, especially those found in human EEC syndrome,
correspond very well with hot spot mutations found in the p53
gene (2, 4). For instance, the missense mutations creating
R204W, R304W, and C306R substitutions in the p63 DNA-
binding domain correspond to R175, R273, and C275 of p53,
respectively. These DNA-binding-defective TAp63 proteins
are highly stable, thus supporting the notion that specific
FIG. 8. Induction of TAp63 promotes degradation of p63 DNA-binding mutant. Doxycycline-repressible stable U2-OS cells, U2-OS-Tet-
TAp63 and U2-OS-Tet-Luc, were transfected with HA-TAp63(R304W). Transfected cells were grown in the presence () or absence () of
doxycycline for 24 h, followed by cycloheximide (CHX) treatment for the indicated times (in hours). Cell lysates were subjected to Western blot
(WB) analysis using antibodies specific for HA tag or actin (A). The data in panel A were subjected to quantitative analysis and presented as a
percentage of remaining protein levels (B). Induction of TAp63 expression in U2-OS-Tet-TAp63 stable cells was assessed by Western blot
analysis for p63 (C).
VOL. 25, 2005 TAp63 PROTEIN DEGRADATION 6161
 o
n
 August 22, 2014 by M
AIN LIBRARY
http://m
cb.asm
.org/
D
ow
nloaded from
 
DNA-binding activity, while being a prerequisite for TAp63-
mediated transcription, is critical for its protein degradation.
Alternatively, it is possible that interaction of TAp63 with
DNA is required for its protein degradation in a manner sim-
ilar to some transcription factors, such as estrogen receptor,
Myc, and VP16, whose DNA-binding activity is critical for
protein degradation (13, 28, 29, 35). However, our data reveal
that wild-type TAp63 can promote the degradation of a
DNA-binding-defective mutant, suggesting that TAp63 inter-
action with DNA is not a prerequisite for its protein degrada-
tion. Notably, high levels of wild-type p53 or MDM2 have been
shown to promote the degradation of mutant p53 proteins
defective in DNA binding (1, 22).
The N-terminal domain of TAp63 is indispensable for its
protein degradation. The TAp63 mutant, which lacks the
entire transactivation domain and thus is completely inert in
transactivation, is highly stable. Replacement of the TA do-
main of TAp63 with the p53 TA domain in the chimeric
protein p53TA-p63 results in increased protein stability in
cells expressing low levels of MDM2, despite its high transac-
tivation activity, indicating that transcription activity is not
sufficient for p63 protein degradation. In addition, the
TAp63(FWL-A) mutant bearing the point mutations in the
F16-W20-L23 motif also leads to protein stability. Of note, not
only are both TAp63 and TAp63(FWL-A) highly stable
but both are also resistant to the degradation induced by wild-
type TAp63. These data indicate that the TA domain is re-
quired for the degradation of TAp63 protein, probably by
serving as an interaction domain for a p63 transcription target
protein that can induce the degradation of TAp63. Interest-
ingly, a recent study reported that the F16-W20-L23 motif
functions as a protein-protein interaction site with which the
transactivation-inhibitory domain on the C terminus of
TAp63 is able to interact, resulting in stabilization of the
TAp63 protein (31). Importantly, these three hydrophobic
amino acids (F19-W23-L26) within the p53 N terminus are
critical for the MDM2-mediated degradation of p53 protein
(16). Despite the poor homology between the p53 family mem-
bers, those three amino acids are well conserved in p53, p63,
and p73; this may mean that MDM2 might also be able to bind
the FWL motif and promote p63 protein degradation. How-
ever, our data indicate that MDM2 is not required for p63
degradation, as evidenced by the observation that p63 protein
can be degraded equally well in p53/ MDM2/ MEF and
wild-type MEF. These data are consistent with the observa-
tions indicating that overexpression of MDM2 does not lead to
p63 protein instability (3, 18).
The notion that p63 is regulated by a feedback loop is fur-
ther supported by the observation that the TAp63 mutant
can significantly inhibit the transactivation activity of the wild-
FIG. 9. TAp63 exhibits dominant-negative effects on the trans-
activation activity and protein stability of wild-type TAp63.
(A) U2-OS cells were cotransfected with Myc-TAp63 and HA-
TAp63 (A) or HA-TAp63(R304W). Cells were then treated with
cycloheximide (CHX) for the indicated times (in hours). Cell lysates
were subjected to Western blot (WB) analysis using an monoclonal
antibody specific for Myc. (B) Saos-2 cells were cotransfected with the
indicated plasmids in the presence of Bax-Luciferase and -galactosi-
dase plasmids. The luciferase activity was normalized to -galactosi-
dase activity and reported as an increase in activation (mean 	 stan-
dard deviation [error bar]). Vec, vector; WT, wild-type TAp63; TA,
HA-TAp63; R304W, HA-TAp63(R304W).
FIG. 10. Feedback model for TAp63 regulation. p53 activates the
expression of MDM2 which in turn binds to the N-terminal transacti-
vation domain of p53 to promote proteasome-dependent degradation.
Similarly, TAp63 binds to a subset of specific DNA promoters and
activates transcription of downstream target genes, one of which en-
codes protein X. Protein X interacts with the TA domain of TAp63
and promotes its protein degradation via proteasome-dependent path-
way. Since TAp63 contains a unique transactivation domain that is
distinct from p53, MDM2 is unable to promote degradation of
TAp63. TAp63 can bind DNA but is unable to transactivate,
thereby acting as a dominant-negative mutant.
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type TAp63 and lead to its protein stabilization. It is possible
that excess expression of TAp63 may occupy the promoter
regions to which the transactivation p63 normally binds and
thereby block TAp63-mediated transcription, which may in
turn suppress the expression of proteins involved in p63 pro-
tein degradation (Fig. 10). Interestingly, a recent study showed
that the transactivation activity of p73 is also critical for p73
protein degradation (37). It is plausible that cells may have
developed similar feedback regulation mechanisms during evo-
lution in regulation of p53 family protein expression despite
their distinct biological functions.
It has been established that certain unstable transcription
factors contain the degron sequences in the transactivation
domains so that transcription can be coupled to proteolysis (17,
23, 30). Our data demonstrated that TAp63 degradation is
also tightly coupled to its transcriptional activity, which may
partially explain the low levels of expression of transactivation-
active p63 isoforms in most tissues and cell lines. Recent stud-
ies have demonstrated that among the p63 proteins TAp63
isoforms are the first to be expressed during embryogenesis
and are required for commitment to an epithelial stratification
program. Np63 is the predominant isoform expressed in the
basal cells of many epithelial tissues (14, 20). Since TAp63
isoforms seem to inhibit terminal differentiation, their activi-
ties must be counterbalanced by various mechanisms, such as
transcription-coupled degradation of TAp63 and expression of
Np63 in neutralizing TAp63, to allow cells to respond to
signals required for the maturation of embryonic epidermis. It
is possible that uncontrolled expression of transactivation-po-
tent p63 isoforms leads to adverse effects on cells, since
TAp63 has been shown as an inducer for apoptosis (8, 39).
Interestingly, the p63 mutations in the DNA-binding domain
observed in several dominant human syndromes are highly
stable. It is conceivable that these mutations may regulate the
function of p53 family proteins to disrupt normal cell prolifer-
ation and development.
Although our data indicate the TAp63 protein stability is
tightly controlled by its transcriptional activity, the precise mo-
lecular mechanism, however, remains to be elucidated.
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